Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 1 1

Status

Completed 3Unknown 2Terminated 1

Sponsor Class

OTHER 9INDUSTRY 3OTHER_GOV 2

Study Type

Interventional 3

Sponsor

Conditions

Pain 2Cancer Pain 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Hydromorphone × Clear all
NCT01824524 2014-08-15

A Pharmacokinetic and Safety Study of Osmotic Release Oral System (OROS) Hydromorphone in Non-Opioid Tolerant Chinese Participants With Cancer

Xian-Janssen Pharmaceutical Ltd.

Phase 1 Completed
12 enrolled

Pain

NCT01205126 2014-02-03

An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
260 enrolled 12 charts

Pain

NCT00766831 2013-10-23

An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain

Janssen Korea, Ltd., Korea

Phase 4 Completed
190 enrolled 17 charts

Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡